Founded with the mission to revolutionize disease diagnosis and treatment, Adela leverages innovative genome-wide methylation enrichment technology to develop accessible blood tests for cancer and other high-morbidity conditions. Initially focusing on the entire cancer continuum, Adela aims to enhance detection, diagnosis, and disease management through its scalable platform. This technology was pioneered by Dr. Daniel De Carvalho at the Princess Margaret Cancer Centre, underscoring Adela's commitment to cutting-edge scientific research.
Adela has attracted notable attention from key figures in the medical and biotech fields, including its Chief Scientific Officer, Dr. Daniel De Carvalho. The company has achieved significant milestones in developing a platform that can detect minimal residual disease (MRD) post-surgery, guiding adjuvant treatment, and monitoring for cancer recurrence. Adela's impact lies in its potential to transform cancer care by providing early, accurate, and non-invasive diagnostic options, addressing a critical unmet need in oncology.
